The company projects initial revenue generation from its Sildenafil Cream formulation in Q4 2025, backed by its 503B compounding strategy. Daré plans to provide updates in Q2 2025 on strategic ...

Since 2022, four GLP-1 drugs, including those indicated for weight loss, have been on FDA’s drug shortage list due to extraordinarily high patient demand. The shortage has, in turn, resulted in ...

The Food and Drug Administration said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of tirzepatide — the active ingredient in Eli Lilly’s ...

Still life of Ozempic and Wegovy. Both are injectable prescription weight loss medicines. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) As demand surges for semaglutide ...

Flush with funding and surging demand, compounding pharmacies are attracting capital from private equity firms, venture capital firms, and hospitals, reshaping the pharmaceutical power dynamic from ...